A Phase I Study of SHR-3836 in Patients With Multiple Myeloma

Exclusion Criteria

• •1. Diagnosis of amyloidosis, plasma cell leukemia, Waldenström's macroglobulinemia, or POEMS syndrome.
• •2. Central nervous system involvement by tumor.
• •3. History of ≥ Grade 3 CRS with prior T-cell redirecting therapy.
• •4. Requirement for dialysis or plasmapheresis within 14 days prior to study drug.
• •5. Prior treatment-related AEs not recovered to ≤ Grade 1 (except alopecia, peripheral neuropathy, or controlled endocrinopathies).
• •6. Concurrent participation in another clinical study.
• •7. Prior anti-tumor therapy within specified washout periods.
• •8. Major surgery within 28 days prior to informed consent or planned during the study.
• •9. Live attenuated vaccine within 4 weeks prior to first dose or planned during the study.
• •10. Significant comorbidity that in the investigator's judgment would interfere with study participation or safety.
• •11. Active autoimmune disease (except controlled type I diabetes, hypothyroidism, or vitiligo).
• •12. Active infection.
• •13. Known hypersensitivity or contraindication to SHR-3836.